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Assessment of the Right Ventricular
Function and Mass Using Cardiac 
Multi-Detector Computed Tomography in
Patients with Chronic Obstructive
Pulmonary Disease 
Objective: We wanted to assess the relationship between measurements of
the right ventricular (RV) function and mass, with using cardiac multi-detector
computed tomography (MDCT) and the severity of chronic obstructive pulmonary
disease (COPD) as determined by the pulmonary function test (PFT).
Materials and Methods: Measurements of PFT and cardiac MDCT were
obtained in 33 COPD patients. Using the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) classification, the patients were divided into three groups
according to the severity of the disease: stage I (mild, n = 4), stage II (moderate, n
= 15) and stage III (severe, n = 14). The RV function and the wall mass were
obtained by cardiac MDCT. The results were compared among the groups using
the Student-Newman-Keuls method. Pearson’s correlation was used to evaluate
the relationship between the right ventricular ejection fraction (RVEF) and the wall
mass results with the PFT results. P-values less than 0.05 were considered sta-
tistically significant. 
Results: The RVEF and mass were 47 3% and 41 2 g in stage I, 46 6%
and 46 5 g in stage II, and 35 5% and 55 6 g in stage III, respectively. The
RVEF was significantly lower in stage III than in stage I and II (p < 0.01). The RV
mass was significantly different among the three stages, according to the disease
severity of COPD (p < 0.05). The correlation was excellent between the MDCT
results and forced expiratory volume in 1 sec (r = 0.797 for RVEF and r =  0.769
for RV mass) and forced expiratory volume in 1 sec to the forced vital capacity (r
= 0.745 for RVEF and r =  0.718 for RV mass).
Conclusion: Our study shows that the mean RV wall mass as measured by
cardiac MDCT correlates well with the COPD disease severity as determined by
PFT. 
he evaluation of the right ventricular (RV) function and mass is clinically
important for management of chronic obstructive pulmonary disease
(COPD) because this disease is known to be complicated by development
of cor pulmonale. The development of cor pulmonale in these patients is associated
with mortality, and proper treatment may improve the quality of the patient’s life and
prolong the survival (1 3).
Measurement of RV volumes and mass, either by echocardiography or radionuclide
study, has proven difficult due to the complex RV geometry (4, 5). Furthermore,
emphysema is often encountered in patients with COPD and it may disturb the
transmission of the echocardiographic signals, especially when the emphysema extends
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Abbreviations
COPD = chronic obstructive pulmonary disease,
DLCO = diffuse capacity of the lung for carbon
monoxide, ECG = echocardiogram, EF = ejection
fraction, FEV1 = forced expiratory volume in 1
second, FEV1/FEC = the ratio of the forced
expiratory volume in 1 second to the forecd vital
capacity, GOLD = Global Initiative for Chronic
Obstructive Lung Disease, MDCT = multidetector
computed tomography, MPR = multiplanar
reformation, PFT = pulmonary function test, RV =
right ventricular, RVEDV = right ventricular end-
diastolic volume, RVEF = right ventricular ejection
fraction, RVESV = right ventricular end-systolic
volume, RVSV = right ventricular stroke volume,
SD = standard deviation, VC = vital capacity
Tbetween the heart and the thorax wall (6). 
The recently introduced multi-detector computed
tomography (MDCT) with sub-second rotation times and a
dedicated cardiac reconstruction algorithm has the ability
to acquire thin-section spiral CT coronary angiograms (7,
8). Using the helical scan technique, the image data can be
continuously acquired throughout the entire cardiac cycle.
Thus, the additional end-diastolic and the end-systolic
images can be reconstructed retrospectively from the same
MDCT data for the purposes of the functional analysis.
Previous reports have shown that using cardiac MDCT for
assessment of the RV function is a possible and acceptable
technique (9, 10). 
The purpose of this study was to assess the relationship
between the measurements of the RV function and the
mass with using cardiac MDCT and the disease severity in
patients with COPD, as determined by pulmonary function
test (PFT).
MATERIALS AND METHODS
Patients Selection
This study was approved by the institutional review
boards at our hospitals, and an informed consent in respect
to the PFT and cardiac MDCT was obtained from all the
patients. The data were collected prospectively. From June
2004 to April 2005, 33 patients with COPD underwent the
PFT and cardiac MDCT examinations. The group of the
patients consisted of 29 men and four women, aged from
50 to 71 years (mean age, 62 years). The diagnosis of
COPD was made by the clinical examination, chest
radiographs and lung function parameters based on the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) Workshop Report (11). The following patients
were excluded from our study: patients who had severe
primary cardiac disease, diffuse or focal parenchymal
abnormalities affecting more than one segment, and
pleural effusions.
Pulmonary Function Test
Pulmonary function test was performed in a dedicated
pulmonary function laboratory, under the supervision of a
certified pulmonary technologist, before the cardiac MDCT
examinations. For all the patients, the interval between the
PFT and cardiac MDCT examinations was less than one
week.
The PFT indexes were measured using a spirometer
(Vmax 229, Sensormedics, Yorda Linda, CA). The PFT
parameters included the vital capacity (VC), the forced
expiratory volume in 1 sec (FEV1), the ratio of the forced
expiratory volume in 1 sec to the forced vital capacity
(FEV1/FVC) and the diffusing capacity of the lung for
carbon monoxide (DLCO). The values of VC, FEV1,
FEV1/FVC and DLCO were expressed as the percentages
of the predicted values (percentage of predicted). 
All the patients were divided into three groups, accord-
ing to the disease severity, based on the GOLD classifica-
tions (11); stage I (mild, FEV1/FVC < 70% of predicted,
and FEV1/predicted FEV1 > 0.8), stage II (moderate,
FEV1/FVC < 70% of predicted, and 0.3  FEV1/predicted
FEV1 < 0.8) and stage III (severe, FEV1/FVC < 70% of
predicted, and FEV1/predicted FEV1 < 0.3 or
FEV1/predicted FEV1 < 0.5 with respiratory failure or
clinical signs of right heart failure). 
Multi-Detector Computed Tomography Examination
The cardiac MDCT scan was performed using a sixteen-
slice helical CT (Somatom Sensation 16, software version
VA20, Siemens Medical Solutions, Forchheim, Germany)
in the caudo-cranial direction within a single breath-hold.
The patient’s echocardiogram (ECG) trace was simultane-
ously recorded. The mean heart rate of the patients was 67
12 beats per minute (range 52 97 beats/min) during the
CT examination. No beta-blocker was used to control the
heart rate. The scan parameters were as follows: 420 ms
the gantry rotation time, 120 kV, 500 mAs, 0.75 mm slice
collimation, 1 mm slice width, and 2.8 mm table
feed/rotation. The contrast solution was composed of 100
ml of contrast media (Ultravist 300; Schering, Berlin,
Germany), and it was mixed with 20 mL of normal saline;
this was administered intravenously at a rate of 4.5 ml for
the first 20 seconds followed by the rate of 1.5 ml for 20
seconds using a power injection (Envision CT, Medrad,
Pittsburgh, PA). As a single head power injector was used
in this study, the contrast medium was diluted with saline
in order to reduce the streaky artifact in the right heart
caused by a high concentration of contrast media. 
The image reconstruction was performed on the
scanner’s workstation using commercially available
software (Syngo , Somaris/5 , Siemens Medical Solutions,
Germany). We used a partial scan algorithm, which
provided a heart rate dependent temporal resolution
between 70 msec and 210 msec from the 420-millisecond
gantry rotation. The reconstruction parameters were as
follows: a 1 mm slice thickness, a 0.5 mm increment, a 512
512 pixels image matrix, a medium smooth kernel and a
20 cm field of view. 
In order to identify the maximum systolic contraction
and diastolic relaxation phases, we reconstructed two
image sets based on the retrospective ECG triggering. The
end-systolic phase was reconstructed when the reconstruc-
tion window was located at the halfway point of the
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was reconstructed when the window was at the start point
of the QRS complex on the ECG. 
The multiplanar reformation (MPR) images in the 4-
chamber view and the long and short axis orientation were
reformatted using the scanner’s standard 3D-software.
From the short axis orientation, the MPR images with a
section thickness of 6 mm, without gap, were produced to
encompass the entire RV from the base to the apex (Fig. 1).
Multi-Detector Computed Tomography Data Analysis
Two radiologists evaluated the right ventricular end-
systolic volume and right ventricular end-diastolic volume
independently with using commercially available software
(Argus , Wizard , Siemens Medical Solutions, Germany).
The endocardial contours of all the systolic and diastolic
short-axis reformation images were manually traced on the
analysis software screen. Both papillary muscles and
trabeculations were considered as a part of the RV cavity.
The basic problem of the short-axis method is determina-
tion of the basal slice. Because of the parallel orientation of
the tricuspid valve to the short axis, difficulties may be
faced for detecting the valve itself and thus the basal slice.
Therefore, the areas containing a recognizable RV outflow
tract below the pulmonary valve were included in the
ventricular portion. The right ventricular stroke volume
and ejection fraction were obtained by the analysis
software. The measurement of the RV myocardial mass
was performed from a short-axis plane as described in a
previous report (8). The endocardial and epicardial
volumes were obtained with using commercially available
software by manually tracing the endocardial and epicar-
dial contours (Fig. 2). The ventricular septum was not
considered as a part of the RV, and it was not included in
the mass measurements. The myocardial mass was assessed
using the following equation: myocardial mass = (epicar-
dial volume-endocardial volume) *1.05 (the specific
gravity of myocardium).
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Fig. 1. Short-axis multiplanar reforma-
tion images in the end-diastolic and the
end-systolic phases. 
AB
Fig. 2. Measurement of the right ventric-
ular myocardial volume. The end
systolic multiplanar reformation (A) and
the end diastolic multiplanar reformation
(B) images in the short-axis sections
with markers indicate how the endocar-
dial and the epicardial borders of these
sections were traced. The myocardial
mass was assessed using the following
equation: myocardial mass = (epicardial
volume endocardial volume) *1.05 (the
specific gravity of myocardium).
ABStatistical Analysis 
The mean volumetric measurements by the two
observers were used for the analysis. To evaluate the
statistically significant differences in the RV volumes, the
ejection fraction and the mass among the three COPD
patient groups, one-way ANOVA with the Student-
Newman-Keuls method was used. The right ventricular
ejection fraction results and the mass results were
correlated with the PFT results using Pearson’s correlation.
P-values less than 0.05 were considered statistically signifi-
cant. 
Pearson’s correlation and the Bland-Altman analysis were
used to determine the correlation and limits of agreement
between the two observers, who used the two-phase
reconstruction method of cardiac MDCT for the right
ventricular ejection fraction and mass measurements. The
Wilcoxon signed rank test was used to evaluate statistically
significant differences in the right ventricular ejection
fraction and the mass between the two observers. P-values
less than 0.05 were considered statistically significant.
SPSS software (Version 10.0; Statistical Package for the
Social Sciences, Chicago, IL) was used for the statistical
evaluations. 
RESULTS
The short axis reformations of cardiac MDCT allowed
clear delineation of the endocardial contours of the RV in
all the COPD patients. In some patients, the stair-step
artifacts were visualized, which were more prominent in
stage III than in stage I or II. However, there were no
obstacles in the RV volume and mass evaluation.
The results of PFT are summarized in Table 1. 
Table 2 shows the results of the right ventricular end-
diastolic volume, right ventricular end-systolic volume,
right ventricular stoke volume, right ventricular ejection
fraction, and right ventricular mass in 33 patients with
COPD. The right ventricular end-diastolic volume was
significantly lower in stage III than in stage I and II (p <
0.01), whereas the RVESV was not significantly different
among the three stages (p > 0.05). In concordance with
this, the RVEF was significantly lower in stage III than in
stage I and II (p < 0.01). The RV mass was significantly
different among the three stages, according to the COPD
Hur et al.
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Table 1.  Results of the Pulmonary Function Tests in 33 Patients with Chronic Obstructive Pulmonary Disease
Parameter Stage I (n = 4) Stage II (n = 15) Stage III (n = 14)
VC (% of predicted) 97.3 4 85.4 13 71.9 15
FEV1 (% of predicted) 82.2 2 53.5 11 32.3 70
FEV1/FVC (% of predicted) 65.2 2 52.0 60 44.2 13
DLCO (% of predicted)  71.3 2 48.3 10 36.7 12
Note. VC = vital capacity, FEV1 = forced expiratory volume in 1 second, FEV1/FVC = the ratio of the forced expiratory volume in 1 
second to the forced vital capacity, DLCO = diffusing capacity of the lung for carbon monoxide
Stage I- FEV1/FVC < 70% of predicted, FEV1/predicted FEV1 > 0.8, 
Stage II- FEV1/FVC < 70% of predicted, 0.3 FEV1/predicted FEV1 < 0.8, 
Stage III- FEV1/FVC < 70% of predicted, FEV1/predicted FEV1 < 0.3 or FEV1/predicted FEV1 < 0.5 with respiratory failure or clinical
signs of right heart failure
Table 2. Right Ventricular Measurements Obtained with Multidetector CT Imaging in 33 Patients with Chronic Obstructive
Pulmonary Disease
Measurement Stage I (n = 4) Stage II (n = 15) Stage III (n = 14) P-value
End-diastolic volume (mL) 135 10 126 16 101 11* 0.002
End-systolic volume (mL) 070 9 067 13 062 12 0.651
RV stroke volume (mL) 064 7 059 11 036 7* 0.005
RV ejection fraction (%) 047 3 046 6 035 5* 0.009
RV wall mass (g) 041 2* 046 5* 055 6* 0.008
Note. Stage I- FEV1/FVC < 70% of predicted, FEV1/predicted FEV1 > 0.8, 
Stage II- FEV1/FVC < 70% of predicted, 0.3 FEV1/predicted FEV1 < 0.8,
Stage III- FEV1/FVC < 70% of predicted, FEV1/predicted FEV1 < 0.3 or FEV1/predicted FEV1 < 0.5 with respiratory failure or clinical signs of right heart
failure).
n = number of patients, 
* Significant differences among the three stages, 
No significant differences between two stages, Mean values +/ standard deviation (SD) are indicated. One-way ANOVA with the Student-Newman-
Keuls method was performed to evaluate the difference among the three stages, and the differences are considered significant at the p < 0.05 level. disease severity (p < 0.05). There were no significant
differences between stage I and stage II in the right ventric-
ular end-diastolic volume, right ventricular end-systolic
volume, right ventricular stroke volume, and right ventric-
ular ejection fraction (p > 0.05). 
Correlation was excellent between the MDCT results
and the FEV1 (r = 0.797 for RVEF and r =  0.769 for RV
mass) (Fig. 3) and FEV1/FVC (r = 0.745 for RVEF and r = 
0.718 for RV mass) (Fig. 4).
The interobserver agreement was good, with a correla-
tion coefficient of 0.907 for RVEF and a correlation coeffi-
cient of 0.894 for RV wall mass. There were no significant
differences between the RVEF and RV mass (p = 0.74 for
RVEF, and p = 0.71 for RV mass, respectively) (Table 3).
DISCUSSION
This study shows that the mean RV wall mass and EF, as
Right Ventricular Function and Mass Evaluation Using Cardiac MDCT in COPD
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Fig. 3. The relationship between the measurements of the RV ejection fraction and the mass, and the FEV1 in 33 patients with COPD. 
A. The relationship between the measurements of the RV ejection fraction and FEV1, with the correlation coefficient of 0.797. 
B. The relationship between the measurements of the RV mass and FEV1, with the correlation coefficient of  0.769.
AB
Fig. 4. The relationship between the measurements of the RV ejection fraction and the mass, and the FEV1/FVC in 33 patients with
COPD. 
A. The relationship between the measurements of the RV ejection fraction and FEV1/FVC, with the correlation coefficient of 0.745. 
B. The relationship between the measurements of the RV mass and FEV1/FVC, with the correlation coefficient of  0.718.
AB
Table 3. Interobserver Variability of the Right Ventricular
Measurements with Multidetector CT in 33 Patients
with Chronic Obstructive Pulmonary Disease
Measurement (n=33) rP -value B-A Analysis W(p)
RV ejection fraction (%)  0.907 0.001 0.1 6.9 0.74
RV wall mass (g) 0.894 0.001 0.1 7.2 0.71
Note. n = number of patients, B-A Analysis = Bland-Altman analysis, 
W = Wilcoxon signed ranks testmeasured by MDCT scan, correlate with the COPD disease
severity.
It is known that RV hypertrophy occurs in numerous
disorders and conditions, including valvular disease, lung
disease, and chronic left-sided heart failure (12, 13).
Chronic hypoxemia, which is not unusual in patients with
COPD, leads to hypoxic pulmonary vasoconstriction and
later to structural changes in the pulmonary vasculature.
Thus it contributes to the development of pulmonary
arterial hypertension and causes an increased RV afterload
(4). RV hypertrophy may results from a response to this
RV pressure overload (14, 15). In a recent study by Vonk-
Noordegraaf et al. (16), RV hypertrophy is described as the
earliest sign of the RV pressure overload in COPD patients
with mild hypoxemia. However, RVEF is well preserved in
most patients with advanced emphysema during rest (4,
17 19). Pattynama et al. (17) have described that RVEF is
not decreased in COPD patients, and it is well preserved in
most stable COPD patients. Biernacki et al. (19) also
demonstrated that in patients with stable COPD, despite
the presence of pulmonary hypertension, the RVEF
remained relatively normal. In our study, the RVEF
between stage I (mild COPD patients) and stage II
(moderate COPD patients) was not significantly different
(47 3% vs 46 6%, p > 0.05), whereas it was signifi-
cantly lower in stage III (severe COPD patients). These
results may reflect that with a persistent RV pressure
overload, the compensated RV function falls, which
eventually results in RV failure (4). 
In addition, it has been strongly suggested that even in a
hypertrophied RV, the EF is preserved until relatively late
in the course of COPD (19, 20). However, if RV hypertro-
phy progresses and the RVEDV decreases, the compen-
sated RV function can eventually fall. In our study, the RV
mass was significantly different among the three stages of
the disease severity, and it gradually increased with preser-
vation of RVEF in stage I and stage II (mild and moderate
COPD patients); however, in stage III (severe COPD
patients), the RVEF fell, although the RV mass increased. 
Several imaging modalities, including echocardiograph,
angio-cardiography and radionuclide imaging, have all
been used to evaluate RVEF and the mass; however, the
success of these techniques is limited. Because of the
complex shape and substernal location of the RV, it is
difficult to estimate the RV function and mass with most of
the imaging techniques (21). 
Magnetic resonance imaging (MRI) has recently been
introduced for more accurate measurements of the RV
function and the wall mass in COPD patients (17, 18).
Pattynama et al. (17) used MRI to evaluate the RV
function and the wall mass in 17 patients with moderate
COPD. They concluded that detection of RV myocardial
hypertrophy with MRI may aid in the early diagnosis of
cor pulmonale that complicates COPD. The advantages of
cardiac MRI as compared with MDCT are the lack of
radiation exposure, avoidance of iodinated contrast media
and an improved temporal resolution in the evaluation of
the RV volumes and the mass. Furthermore, short-axis
images are readily available, and the secondary reforma-
tions required in cardiac MDCT are not needed with
cardiac MRI. However, cardiac MRI cannot evaluate lung
parenchyma, and it is difficult to perform MRI in patients
with dyspnea and heart failure due to a much longer
examination time.
The recently introduced MDCT scanners have
demonstrated their ability to assess the RV function and
the wall mass (9, 10). Koch et al. (9) demonstrated that the
mean RVEDV, RVESV and RVSV determined with MPR
by 16-detector-row CT correlated well with those parame-
ters measured by cardiac MRI. However, to our
knowledge, there have been no studies that have
evaluated the RV function with using MDCT in COPD
patients. 
Although cardiac MDCT can be used as a modality for
evaluating the RV volume, function and the wall mass in
COPD patients, it has certain limitations in routine use.
Cardiac MDCT requires contrast media to discriminate the
ventricular cavity, and its temporal resolution is inferior to
either electron beam CT or MRI (22). Ritchie et al. (23)
have reported that a temporal resolution of about 20
milliseconds is needed to completely avoid any motion
artifacts in cardiac imaging by CT. Thus, the limited
temporal resolution used in our study may have been
insufficient to acquire a precise end systolic volume.
Furthermore, in COPD patients, dyspnea often makes it
difficult to perform breath-holding more than 10 seconds
long, and the stair step artifact can affect evaluation of the
ventricular function. It is hoped that with technological
developments, the image quality will further improve and
the imaging time will be shortened. Another limitation is
the radiation exposure. The total radiation dose was
calculated to be approximately 4 to 6 mSv, depending on
the scan range and the patient’s body weight.
Our study includes the following limitations. First, the
study population was too small to generalize the results,
especially in respect of the stage I patients (mild COPD
patients). Second, we did not include normal control
subjects for correlation of the RV function. Third, the
MDCT results were not compared with the cardiac MRI
results, which is the accepted gold standard modality.
These problems will need to be solved in future studies. 
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Cardiac MDCT has a potential to become a useful
modality for assessing the RV function and RV myocardial
hypertrophy in COPD patients. Our results show that the
mean RV wall mass measured by cardiac MDCT correlates
well with the disease severity of COPD as determined by
PFT, and that the mean RVEF is significantly lower in
patients with severe COPD than it is in those patients with
mild or moderate COPD.
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